Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck.
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Head and neck cancer; Precancerous conditions
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 10 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 10 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.